Sumant Kulkarni
Stock Analyst at Canaccord Genuity
(2.02)
# 2,968
Out of 4,941 analysts
111
Total ratings
36.36%
Success rate
-6.12%
Average return
Main Sectors:
Stocks Rated by Sumant Kulkarni
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPS COMPASS Pathways | Maintains: Buy | $15 | $4.22 | +255.45% | 4 | Aug 1, 2025 | |
| CRVO CervoMed | Maintains: Buy | $21 → $27 | $9.50 | +184.21% | 6 | Jul 29, 2025 | |
| ATAI Atai Life Sciences | Maintains: Buy | $12 → $11 | $4.13 | +166.67% | 3 | Jul 28, 2025 | |
| CYBN Cybin | Maintains: Buy | $73 → $70 | $7.63 | +817.43% | 8 | Jul 8, 2025 | |
| ANVS Annovis Bio | Maintains: Buy | $26 → $17 | $2.77 | +513.03% | 3 | May 15, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $158 → $160 | $128.96 | +24.07% | 16 | May 6, 2025 | |
| BIIB Biogen | Maintains: Buy | $265 → $220 | $128.93 | +70.64% | 21 | May 2, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $23 → $25 | $11.76 | +112.59% | 6 | Mar 13, 2025 | |
| VYGR Voyager Therapeutics | Maintains: Buy | $14 → $12 | $3.39 | +253.98% | 5 | Mar 13, 2025 | |
| BTAI BioXcel Therapeutics | Maintains: Buy | $112 → $80 | $6.79 | +1,079.07% | 7 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $28 | $12.13 | +130.83% | 4 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $86 → $83 | $3.71 | +2,140.22% | 5 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $14 | $10.15 | +37.93% | 1 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $20 | $13.54 | +47.77% | 3 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $33 | $25.44 | +29.72% | 13 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $150 | $13.47 | +1,014.00% | 4 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $16.60 | - | 2 | Jan 31, 2017 |
COMPASS Pathways
Aug 1, 2025
Maintains: Buy
Price Target: $15
Current: $4.22
Upside: +255.45%
CervoMed
Jul 29, 2025
Maintains: Buy
Price Target: $21 → $27
Current: $9.50
Upside: +184.21%
Atai Life Sciences
Jul 28, 2025
Maintains: Buy
Price Target: $12 → $11
Current: $4.13
Upside: +166.67%
Cybin
Jul 8, 2025
Maintains: Buy
Price Target: $73 → $70
Current: $7.63
Upside: +817.43%
Annovis Bio
May 15, 2025
Maintains: Buy
Price Target: $26 → $17
Current: $2.77
Upside: +513.03%
Neurocrine Biosciences
May 6, 2025
Maintains: Buy
Price Target: $158 → $160
Current: $128.96
Upside: +24.07%
Biogen
May 2, 2025
Maintains: Buy
Price Target: $265 → $220
Current: $128.93
Upside: +70.64%
Zevra Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $23 → $25
Current: $11.76
Upside: +112.59%
Voyager Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $14 → $12
Current: $3.39
Upside: +253.98%
BioXcel Therapeutics
Jan 6, 2025
Maintains: Buy
Price Target: $112 → $80
Current: $6.79
Upside: +1,079.07%
Nov 18, 2024
Maintains: Buy
Price Target: $31 → $28
Current: $12.13
Upside: +130.83%
Nov 14, 2024
Maintains: Buy
Price Target: $86 → $83
Current: $3.71
Upside: +2,140.22%
Sep 16, 2024
Maintains: Buy
Price Target: $16 → $14
Current: $10.15
Upside: +37.93%
May 7, 2024
Maintains: Buy
Price Target: $21 → $20
Current: $13.54
Upside: +47.77%
Mar 12, 2024
Maintains: Buy
Price Target: $40 → $33
Current: $25.44
Upside: +29.72%
Aug 3, 2021
Maintains: Buy
Price Target: $101 → $150
Current: $13.47
Upside: +1,014.00%
Jan 31, 2017
Upgrades: Buy
Price Target: n/a
Current: $16.60
Upside: -